Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yamada
NCT05169710 / 2021-002126-24: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.	Terminated	3	83	Europe, Canada, Japan, US	SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo	Sumitomo Pharma America, Inc., Sunovion Pharmaceuticals Inc.	Depressive Episodes, Bipolar I Depression	10/23	10/23
Yamada, Takahiro
NCT05359081: A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan	Terminated	3	68	Japan	SEP-363856	Sumitomo Pharma Co., Ltd.	Schizophrenia	03/24	03/24
Suto, Yasuhiko
NCT05359081: A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan	Terminated	3	68	Japan	SEP-363856	Sumitomo Pharma Co., Ltd.	Schizophrenia	03/24	03/24